Top

Quality of Life Research

Gepubliceerd in:

17-12-2019 | Review

How are patient-reported outcomes and symptoms being measured in adults with relapsed/refractory multiple myeloma? A systematic review

Auteurs: Matthew R. LeBlanc, Rachel Hirschey, Ashley Leak Bryant, Thomas W. LeBlanc, Sophia K. Smith

Gepubliceerd in: Quality of Life Research | Uitgave 6/2020

Abstract

Purpose

Patients with relapsed and/or refractory multiple myeloma (RRMM) are living longer due in part to changing treatment patterns. It is important to understand how changing treatment patterns affect patients’ lives beyond extending survival. Research suggests that direct patient report is the best way to capture information on how patients feel and function in response to their disease and its treatment. Therefore, the purpose of this review is to summarize evidence of patients’ experience collected through patient-reported outcomes (PRO) in RRMM patients, and to explore PRO reporting quality.

Methods

We conducted a systematic search to identify manuscripts reporting PROs in RRMM and summarized available evidence. We assessed PRO reporting quality using the Consolidated Standards of Reporting Trials (CONSORT) PRO Extension checklist.

Results

Our search resulted in 30 manuscripts. Thirteen unique PRO measures were used to assess 18 distinct PRO domains. Pain, fatigue, and emotional function were commonly assessed domains though reporting formats limited our ability to understand prevalence and severity of PRO challenges in RRMM. Evaluation of PRO reporting quality revealed significant reporting deficiencies. Several reporting criteria were included in less than 25% of manuscripts.

Conclusions

Existing evidence provides a limited window for understanding the patient experience of RRMM and is further limited by suboptimal reporting quality. Observational studies are needed to describe prevalence, severity and patterns of PROs in RRMM overtime. Future studies that incorporate PROs would benefit from following existing guidelines to ensure that study evidence and conclusions can be fully assessed by readers, clinicians and policy makers.

volgende artikel Capability instruments in economic evaluations of health-related interventions: a comparative review of the literature

Alleen toegankelijk voor geautoriseerde gebruikers

Multiple myeloma relapse is defined as progressive disease following a response to treatment, and refractory disease is defined as failure to respond to treatment, or progressive disease while on treatment or within 60 days of treatment [17].

Siegel, R. L., Miller, K. D., & Jemal, A. (2019). Cancer statistics, 2019. CA: A Cancer Journal for Clinicians,69(1), 7–34. https://doi.org/10.3322/caac.21551.CrossRef

National Cancer Institute (2019). Cancer stat facts: Myeloma. Retrieved 5 May 2019 from https://seer.cancer.gov/statfacts/html/mulmy.html.

Rosenberg, P. S., Barker, K. A., & Anderson, W. F. (2015). Future distribution of multiple myeloma in the United States by sex, age, and race/ethnicity. Blood,125(2), 410–412. https://doi.org/10.1182/blood-2014-10-609461.CrossRefPubMedPubMedCentral

Smith, B. D., Smith, G. L., Hurria, A., Hortobagyi, G. N., & Buchholz, T. A. (2009). Future of cancer incidence in the United States: Burdens upon an aging, changing nation. Journal of Clinical Oncology,27(17), 2758–2765. https://doi.org/10.1200/jco.2008.20.8983.CrossRefPubMed

Siegel, R. L., Miller, K. D., & Jemal, A. (2018). Cancer statistics, 2018. CA: A Cancer Journal for Clinicians,68(1), 7–30. https://doi.org/10.3322/caac.21442.CrossRef

Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., et al. (2008). Cancer statistics, 2008. CA: A Cancer Journal for Clinicians,58(2), 71–96. https://doi.org/10.3322/ca.2007.0010.CrossRef

Kristinsson, S. Y., Anderson, W. F., & Landgren, O. (2014). Improved long-term survival in multiple myeloma up to the age of 80 years. Leukemia,28(6), 1346–1348. https://doi.org/10.1038/leu.2014.23.CrossRefPubMed

Kristinsson, S. Y., Landgren, O., Dickman, P. W., Rangert Derolf, A. R., & Björkholm, M. (2007). Patterns of survival in multiple myeloma: A population-based study of patients diagnosed in Sweden from 1973 to 2003. Journal of Clinical Oncology,25(15), 1993–1999. https://doi.org/10.1200/jco.2006.09.0100.CrossRefPubMed

Kumar, S. K., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., et al. (2008). Improved survival in multiple myeloma and the impact of novel therapies. Blood,111(5), 2516–2520. https://doi.org/10.1182/blood-2007-10-116129.CrossRefPubMedPubMedCentral

10.

Morgan, G. J., & Rasche, L. (2017). Haematological cancer: Where are we now with the treatment of multiple myeloma? Nature Reviews Clinical Oncology,14(8), 461. https://doi.org/10.1038/nrclinonc.2017.82.CrossRefPubMed

11.

American Cancer Society (2018). Cancer Statistics Center: Myeloma. Retrieved June 9 2018 from https://cancerstatisticscenter.cancer.org/?_ga=2.121553931.226068755.1528521260-452354456.1486498770#!/cancer-site/Myeloma.

12.

Kumar, L., Verma, R., & Radhakrishnan, V. R. (2010). Recent advances in the management of multiple myeloma. National Medical Journal of India,23(4), 210–218.

13.

Kent, E. E., Ambs, A., Mitchell, S. A., Clauser, S. B., Smith, A. W., & Hays, R. D. (2015). Health-related quality of life in older adult survivors of selected cancers: Data from the SEER-MHOS linkage. Cancer,121(5), 758–765. https://doi.org/10.1002/cncr.29119.CrossRefPubMed

14.

Manitta, V., Zordan, R., Cole-Sinclair, M., Nandurkar, H., & Philip, J. (2011). The symptom burden of patients with hematological malignancy: A cross-sectional observational study. Journal of Pain and Symptom Management,42(3), 432–442. https://doi.org/10.1016/j.jpainsymman.2010.12.008.CrossRefPubMed

15.

Ramsenthaler, C., Kane, P., Gao, W., Siegert, R. J., Edmonds, P. M., Schey, S. A., et al. (2016). Prevalence of symptoms in patients with multiple myeloma: A systematic review and meta-analysis. European Journal of Haematology,97(5), 416–429. https://doi.org/10.1111/ejh.12790.CrossRefPubMed

16.

Ramsenthaler, C., Osborne, T. R., Gao, W., Siegert, R. J., Edmonds, P. M., Schey, S. A., et al. (2016). The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: A multi-centre study. BMC Cancer,16, 427. https://doi.org/10.1186/s12885-016-2410-2.CrossRefPubMedPubMedCentral

17.

Laubach, J., Garderet, L., Mahindra, A., Gahrton, G., Caers, J., Sezer, O., et al. (2016). Management of relapsed multiple myeloma: Recommendations of the International Myeloma Working Group. Leukemia,30(5), 1005–1017. https://doi.org/10.1038/leu.2015.356.CrossRefPubMed

18.

Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J. S., Castillo, J., et al. (2018). NCCN guidelines insights: Multiple myeloma, version 3.2018. Journal of the National Comprehensive Cancer Network,16(1), 11–20. https://doi.org/10.6004/jnccn.2018.0002.CrossRefPubMed

19.

Kumar, S. K., Rajkumar, V., Kyle, R. A., van Duin, M., Sonneveld, P., Mateos, M. V., et al. (2017). Multiple myeloma. Nature Reviews Disease Primers,3, 17046. https://doi.org/10.1038/nrdp.2017.46.CrossRefPubMed

20.

Kumar, S. K., Therneau, T. M., Gertz, M. A., Lacy, M. Q., Dispenzieri, A., Rajkumar, S. V., et al. (2004). Clinical course of patients with relapsed multiple myeloma. Mayo Clinic Proceedings,79(7), 867–874. https://doi.org/10.1016/s0025-6196(11)62152-6.CrossRefPubMed

21.

Nielsen, L. K., Jarden, M., Andersen, C. L., Frederiksen, H., & Abildgaard, N. (2017). A systematic review of health-related quality of life in longitudinal studies of myeloma patients. European Journal of Haematology,99(1), 3–17. https://doi.org/10.1111/ejh.12882.CrossRefPubMed

22.

Basch, E. (2010). The missing voice of patients in drug-safety reporting. New England Journal of Medicine,362(10), 865–869. https://doi.org/10.1056/NEJMp0911494.CrossRef

23.

Basch, E. (2014). The rationale for collecting patient-reported symptoms during routine chemotherapy. American Society of Clinical Oncology Educational Book,34(1), 161–165. https://doi.org/10.14694/EdBook_AM.2014.34.161.CrossRef

24.

Basch, E., Jia, X., Heller, G., Barz, A., Sit, L., Fruscione, M., et al. (2009). Adverse symptom event reporting by patients vs clinicians: Relationships with clinical outcomes. Journal of the National Cancer Institute,101(23), 1624–1632. https://doi.org/10.1093/jnci/djp386.CrossRefPubMedPubMedCentral

25.

Basch, E. (2018). High compliance rates with patient-reported outcomes in oncology trials submitted to the US Food and Drug Administration. Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djy183.CrossRef

26.

Basch, E., Abernethy, A. P., Mullins, C. D., Reeve, B. B., Smith, M. L., Coons, S. J., et al. (2012). Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. Journal of Clinical Oncology,30(34), 4249–4255. https://doi.org/10.1200/jco.2012.42.5967.CrossRefPubMed

27.

Wilson, I. B., & Cleary, P. D. (1995). Linking clinical variables with health-related quality of life: A conceptual model of patient outcomes. JAMA,273(1), 59–65.CrossRefPubMed

28.

Patrick, D. L., Burke, L. B., Powers, J. H., Scott, J. A., Rock, E. P., Dawisha, S., et al. (2007). Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value in Health,10(Suppl 2), S125–137. https://doi.org/10.1111/j.1524-4733.2007.00275.x.CrossRefPubMed

29.

Basch, E. (2018). Patient-reported outcomes: an essential component of oncology drug development and regulatory review. Lancet Oncology,19(5), 595–597. https://doi.org/10.1016/s1470-2045(18)30141-4.CrossRefPubMed

30.

Basch, E. (2017). Patient-reported outcomes—harnessing patients’ voices to improve clinical care. New England Journal of Medicine,376(2), 105–108. https://doi.org/10.1056/NEJMp1611252.CrossRef

31.

Basch, E. (2016). Missing patients’ symptoms in cancer care delivery—the importance of patient-reported outcomes. JAMA Oncology,2(4), 433–434. https://doi.org/10.1001/jamaoncol.2015.4719.CrossRefPubMed

32.

Calvert, M., Blazeby, J., Altman, D. G., Revicki, D. A., Moher, D., & Brundage, M. D. (2013). Reporting of patient-reported outcomes in randomized trials: The CONSORT PRO extension. JAMA,309(8), 814–822. https://doi.org/10.1001/jama.2013.879.CrossRefPubMed

33.

Kane, R. C., Bross, P. F., Farrell, A. T., & Pazdur, R. (2003). Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. The Oncologist,8(6), 508–513.CrossRefPubMed

34.

Kumar, S. (2006). Progress in the treatment of multiple myeloma. Lancet,367(9513), 791–792. https://doi.org/10.1016/s0140-6736(06)68311-6.CrossRefPubMed

35.

Garrard, J. (2014). Health sciences literature review made easy: The matrix method (4th ed.). Burlington, MA: Jones and Bartlett Learning.

36.

Schulz, K. F., Altman, D. G., & Moher, D. (2010). CONSORT 2010 statement: Updated guidelines for reporting parallel group randomized trials. Annals of Internal Medicine,152(11), 726–732. https://doi.org/10.7326/0003-4819-152-11-201006010-00232.CrossRefPubMed

37.

Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Medicine,6(7), e1000097. https://doi.org/10.1371/journal.pmed.1000097.CrossRefPubMedPubMedCentral

38.

American Cancer Society (2019). Cancer Statistics Center. Retrieved Mar 4 2019 from https://cancerstatisticscenter.cancer.org/?_ga=2.149046513.650737073.1551729015-1327710948.1453219586#!/cancer-site/Myeloma.

39.

Cowan, A. J., Allen, C., Barac, A., Basaleem, H., Bensenor, I., Curado, M. P., et al. (2018). Global burden of multiple myeloma: A systematic analysis for the global burden of disease study 2016. JAMA Oncol,4(9), 1221–1227. https://doi.org/10.1001/jamaoncol.2018.2128.CrossRefPubMedPubMedCentral

40.

Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., et al. (2003). A phase 2 study of bortezomib in relapsed, refractory myeloma. New England Journal of Medicine,348(26), 2609–2617. https://doi.org/10.1056/NEJMoa030288.CrossRef

41.

Dubois, D., Dhawan, R., van de Velde, H., Esseltine, D., Gupta, S., Viala, M., et al. (2006). Descriptive and prognostic value of patient-reported outcomes: The bortezomib experience in relapsed and refractory multiple myeloma. Journal of Clinical Oncology,24(6), 976–982. https://doi.org/10.1200/jco.2005.04.0824.CrossRefPubMed

42.

Alegre, A., Oriol-Rocafiguera, A., Garcia-Larana, J., Mateos, M. V., Sureda, A., Martinez-Chamorro, C., et al. (2012). Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: The Spanish experience. Leukemia and Lymphoma,53(9), 1714–1721. https://doi.org/10.3109/10428194.2012.662643.CrossRefPubMed

43.

Baljevic, M., Zaman, S., Baladandayuthapani, V., Lin, Y. H., de Partovi, C. M., Berkova, Z., et al. (2017). Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma. Annals of Hematology,96(6), 977–985. https://doi.org/10.1007/s00277-017-2980-3.CrossRefPubMedPubMedCentral

44.

Cella, D., McKendrick, J., Kudlac, A., Palumbo, A., Oukessou, A., Vij, R., et al. (2018). Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: Results from the ELOQUENT-2 study. Annals of Hematology. https://doi.org/10.1007/s00277-018-3469-4.CrossRefPubMedPubMedCentral

45.

Stewart, A. K., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., et al. (2016). Health-related quality-of-life results from the open-label, randomized, phase iii aspire trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma. Journal of Clinical Oncology,34(32), 3921–3930. https://doi.org/10.1200/JCO.2016.66.9648.CrossRefPubMedPubMedCentral

46.

Richardson, P., Roy, A., Acharyya, S., Panneerselvam, A., Mendelson, E., Gunther, A., et al. (2017). Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: The case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent. Expert Review of Hematology,10(10), 933–939. https://doi.org/10.1080/17474086.2017.1369399.CrossRefPubMed

47.

Leleu, X., Masszi, T., Bahlis, N. J., Viterbo, L., Baker, B., Gimsing, P., et al. (2018). Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. American Journal of Hematology. https://doi.org/10.1002/ajh.25134.CrossRefPubMed

48.

Costa, L. J., Hari, P. N., & Kumar, S. K. (2016). Differences between unselected patients and participants in multiple myeloma clinical trials in US: A threat to external validity. Leukemia and Lymphoma,57(12), 2827–2832. https://doi.org/10.3109/10428194.2016.1170828.CrossRefPubMed

49.

Hari, P., Romanus, D., Luptakova, K., Blazer, M., Yong, C., Raju, A., et al. (2018). The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed/refractory multiple myeloma in the era of novel therapies. Journal of Geriatric Oncology,9(2), 138–144. https://doi.org/10.1016/j.jgo.2017.09.007.CrossRefPubMed

50.

Mercieca-Bebber, R., Friedlander, M., Calvert, M., Stockler, M., Kyte, D., Kok, P. S., et al. (2017). A systematic evaluation of compliance and reporting of patient-reported outcome endpoints in ovarian cancer randomised controlled trials: Implications for generalisability and clinical practice. Journal of Patient-Reported Outcomes,1(1), 5. https://doi.org/10.1186/s41687-017-0008-3.CrossRefPubMedPubMedCentral

51.

Mercieca-Bebber, R. L., Perreca, A., King, M., Macann, A., Whale, K., Soldati, S., et al. (2016). Patient-reported outcomes in head and neck and thyroid cancer randomised controlled trials: A systematic review of completeness of reporting and impact on interpretation. European Journal of Cancer,56, 144–161. https://doi.org/10.1016/j.ejca.2015.12.025.CrossRefPubMed

52.

Rees, J. R., Whale, K., Fish, D., Fayers, P., Cafaro, V., Pusic, A., et al. (2015). Patient-reported outcomes in randomised controlled trials of colorectal cancer: An analysis determining the availability of robust data to inform clinical decision-making. Journal of Cancer Research and Clinical Oncology,141(12), 2181–2192. https://doi.org/10.1007/s00432-015-1970-x.CrossRefPubMedPubMedCentral

53.

Efficace, F., Feuerstein, M., Fayers, P., Cafaro, V., Eastham, J., Pusic, A., et al. (2014). Patient-reported outcomes in randomised controlled trials of prostate cancer: Methodological quality and impact on clinical decision making. European Urology,66(3), 416–427. https://doi.org/10.1016/j.eururo.2013.10.017.CrossRefPubMed

54.

Bylicki, O., Gan, H. K., Joly, F., Maillet, D., You, B., & Peron, J. (2015). Poor patient-reported outcomes reporting according to CONSORT guidelines in randomized clinical trials evaluating systemic cancer therapy. Annals of Oncology,26(1), 231–237. https://doi.org/10.1093/annonc/mdu489.CrossRefPubMed

55.

Jagannath, S., Barlogie, B., Berenson, J., Siegel, D., Irwin, D., Richardson, P. G., et al. (2004). A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. British Journal of Haematology,127(2), 165–172. https://doi.org/10.1111/j.1365-2141.2004.05188.x.CrossRefPubMed

56.

Richardson, P. G., Briemberg, H., Jagannath, S., Wen, P. Y., Barlogie, B., Berenson, J., et al. (2006). Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. Journal of Clinical Oncology,24(19), 3113–3120. https://doi.org/10.1200/jco.2005.04.7779.CrossRefPubMed

57.

Waage, A., Gimsing, P., Juliusson, G., Turesson, I., Gulbrandsen, N., Eriksson, T., et al. (2004). Early response predicts thalidomide efficiency in patients with advanced multiple myeloma. British Journal of Haematology,125(2), 149–155. https://doi.org/10.1111/j.1365-2141.2004.04879.x.CrossRefPubMed

58.

Lee, S. J., Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., San Miguel, J. F., et al. (2008). Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. British Journal of Haematology,143(4), 511–519. https://doi.org/10.1111/j.1365-2141.2008.07378.x.CrossRefPubMed

59.

Richardson, P. G., Sonneveld, P., Schuster, M. W., Stadtmauer, E. A., Facon, T., Harousseau, J. L., et al. (2009). Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: Impact of a dose-modification guideline. British Journal of Haematology,144(6), 895–903. https://doi.org/10.1111/j.1365-2141.2008.07573.x.CrossRefPubMed

60.

Vij, R., Horvath, N., Spencer, A., Taylor, K., Vadhan-Raj, S., Vescio, R., et al. (2009). An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma. American Journal of Hematology,84(10), 650–656. https://doi.org/10.1002/ajh.21509.CrossRefPubMed

61.

Hjorth, M., Hjertner, O., Knudsen, L. M., Gulbrandsen, N., Holmberg, E., Pedersen, P. T., et al. (2012). Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: A randomized study. European Journal of Haematology,88(6), 485–496. https://doi.org/10.1111/j.1600-0609.2012.01775.x.CrossRefPubMedPubMedCentral

62.

Safaee, R., Ahmadzadeh, A., Sharifian, R., Emami, A., Yekaninejad, M. S., Jalili, M. H., et al. (2012). Combination of cyclophosphamide, etoposide, carboplatin and dexamethasone as a salvage regimen for refractory multiple myeloma patients: A comparison with a historical control group. Hematology Reports,4(3), e14. https://doi.org/10.4081/hr.2012.e14.CrossRefPubMedPubMedCentral

63.

Vij, R., Siegel, D. S., Jagannath, S., Jakubowiak, A. J., Stewart, A. K., McDonagh, K., et al. (2012). An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. British Journal of Haematology,158(6), 739–748. https://doi.org/10.1111/j.1365-2141.2012.09232.x.CrossRefPubMedPubMedCentral

64.

Vij, R., Wang, M., Kaufman, J. L., Lonial, S., Jakubowiak, A. J., Stewart, A. K., et al. (2012). An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood,119(24), 5661–5670. https://doi.org/10.1182/blood-2012-03-414359.CrossRefPubMedPubMedCentral

65.

Richardson, P. G., Schlossman, R. L., Alsina, M., Weber, D. M., Coutre, S. E., Gasparetto, C., et al. (2013). PANORAMA 2: Panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood,122(14), 2331–2337. https://doi.org/10.1182/blood-2013-01-481325.CrossRefPubMed

66.

Callander, N., Markovina, S., Eickhoff, J., Hutson, P., Campbell, T., Hematti, P., et al. (2014). Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: A study from the Wisconsin Oncology Network. Cancer Chemotherapy and Pharmacology,74(4), 875–882. https://doi.org/10.1007/s00280-014-2550-5.CrossRefPubMedPubMedCentral

67.

Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., et al. (2015). Elotuzumab therapy for relapsed or refractory multiple myeloma. New England Journal of Medicine,373(7), 621–631. https://doi.org/10.1056/NEJMoa1505654.CrossRef

68.

Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Spicka, I., Oriol, A., et al. (2015). Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. New England Journal of Medicine,372(2), 142–152. https://doi.org/10.1056/NEJMoa1411321.CrossRef

69.

Weisel, K., Dimopoulos, M., Song, K. W., Moreau, P., Palumbo, A., Belch, A., et al. (2015). Pomalidomide and low-dose dexamethasone improves health-related quality of life and prolongs time to worsening in relapsed/refractory patients with multiple myeloma enrolled in the MM-003 randomized phase III trial. Clinical Lymphoma, Myeloma and Leukemia,15(9), 519–530. https://doi.org/10.1016/j.clml.2015.05.007.CrossRefPubMed

70.

Moreau, P., Masszi, T., Grzasko, N., Bahlis, N. J., Hansson, M., Pour, L., et al. (2016). Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. New England Journal of Medicine,374(17), 1621–1634. https://doi.org/10.1056/NEJMoa1516282.CrossRef

71.

Robinson, D., Jr., Orlowski, R. Z., Stokes, M., He, J., Huse, S., Chitnis, A., et al. (2017). Economic burden of relapsed or refractory multiple myeloma: Results from an international trial. European Journal of Haematology,99(2), 119–132. https://doi.org/10.1111/ejh.12876.CrossRefPubMed

72.

Basile, A., Tsetis, D., Cavalli, M., Fiumara, P., Di Raimondo, F., Coppolino, F., et al. (2010). Sacroplasty for local or massive localization of multiple myeloma. Cardiovascular and Interventional Radiology,33(6), 1270–1277. https://doi.org/10.1007/s00270-009-9761-x.CrossRefPubMed

73.

Briani, C., Torre, C. D., Campagnolo, M., Lucchetta, M., Berno, T., Candiotto, L., et al. (2013). Lenalidomide in patients with chemotherapy-induced polyneuropathy and relapsed or refractory multiple myeloma: Results from a single-centre prospective study. Journal of the Peripheral Nervous System,18(1), 19–24. https://doi.org/10.1111/jns5.12002.CrossRefPubMed

74.

Samuelson, C., O’Toole, L., Boland, E., Greenfield, D., Ezaydi, Y., Ahmedzai, S. H., et al. (2016). High prevalence of cardiovascular and respiratory abnormalities in advanced, intensively treated (transplanted) myeloma: The case for ‘late effects’ screening and preventive strategies. Hematology,21(5), 272–279. https://doi.org/10.1080/10245332.2015.1122258.CrossRefPubMed

75.

Leleu, X., Kyriakou, C., Vande Broek, I., Murphy, P., Bacon, P., Lewis, P., et al. (2017). Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment. Blood Cancer Journal,7(3), e543. https://doi.org/10.1038/bcj.2017.20.CrossRefPubMedPubMedCentral

Titel: How are patient-reported outcomes and symptoms being measured in adults with relapsed/refractory multiple myeloma? A systematic review
Auteurs: Matthew R. LeBlanc
Rachel Hirschey
Ashley Leak Bryant
Thomas W. LeBlanc
Sophia K. Smith
Publicatiedatum: 17-12-2019
Uitgeverij: Springer International Publishing
Gepubliceerd in: Quality of Life Research / Uitgave 6/2020
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-019-02392-6

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Purpose

Methods

Results

Conclusions

Log in om toegang te krijgen

Andere artikelen Uitgave 6/2020

Patient acceptance and outcome of mental health screening in Swedish adults with cystic fibrosis

Whom should we ask? A systematic literature review of the arguments regarding the most accurate source of information for valuation of health states

Health-related quality of life in patients with myalgic encephalomyelitis/chronic fatigue syndrome: an Australian cross-sectional study

Qualitative study of patients with venous malformations: symptom experiences and content validity of patient-reported outcome measures

Social inequalities in health-related quality of life among people aging with HIV/AIDS: the role of comorbidities and disease severity

Oral health-related quality of life of patients after heart transplantation and those with heart failure is associated with general health-related quality of life: a cross-sectional study